Next Article in Journal
Roles for Pathogen Interference in Influenza Vaccination, with Implications to Vaccine Effectiveness (VE) and Attribution of Influenza Deaths
Previous Article in Journal
COVID-19 in Older Individuals Requiring Hospitalization
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Infectious Disease Reports
Volume 14
Issue 5
10.3390/idr14050075
idr-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

HIV and Mediterranean Zoonoses: A Review of the Literature

by
Ylenia Russotto
1,
Cristina Micali
1,*,
Giovanni Francesco Pellicanò
2,
Giuseppe Nunnari
1 and
Emmanuele Venanzi Rullo
1
1
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy
2
Department of Human Pathology of the Adult and the Developmental Age “G. Barresi”, University of Messina, 98124 Messina, Italy
*
Author to whom correspondence should be addressed.
Infect. Dis. Rep. 2022, 14(5), 694-709; https://doi.org/10.3390/idr14050075
Submission received: 18 July 2022 / Revised: 21 August 2022 / Accepted: 14 September 2022 / Published: 16 September 2022
(This article belongs to the Section Viral Infections)
Versions Notes

Abstract

:
A zoonosis is an infectious disease that has jumped from a non-human animal to humans. Some zoonoses are very common in the Mediterranean area and endemic in specific regions, so they represent an important problem for public health. Human Immunodeficiency Virus (HIV) is a virus that has originated as a zoonosis and is now diffused globally, with the most significant numbers of infected people among the infectious diseases. Since the introduction of antiretroviral therapy (ART), the history for people living with HIV (PLWH) has changed drastically, and many diseases are now no different in epidemiology and prognosis as they are in not-HIV-infected people. Still, the underlying inflammatory state that is correlated with HIV and other alterations related to the infection itself can be a risk factor when infected with other bacteria, parasites or viruses. We reviewed the literature for infection by the most common Mediterranean zoonoses, such as Campylobacter, Salmonella, Brucella, Rickettsia, Borrelia, Listeria and Echinococcus, and a possible correlation with HIV. We included Monkeypox, since the outbreak of cases is becoming a concern lately. We found that HIV may be related with alterations of the microbiome, as for campylobacteriosis, and that there are some zoonoses with a significant prevalence in PLWH, as for salmonellosis.

1. Introduction

A zoonosis, according to the World Health Organization (WHO), is defined as an infectious disease that has jumped from a non-human animal to a human and, therefore, a disease that is transmissible from animal to humans. Some infectious diseases began as a zoonosis and then developed as human-to-human transmitted diseases; among these there is human immunodeficiency virus (HIV), which developed as a result of multiple cross-species transmissions from SIV (simian immunodeficiency virus), naturally infecting African primates [1].
The definition provided by WHO requires a bit of narrowing to differentiate the various kinds of zoonoses. Zoonoses commonly indicate those diseases caused by pathogens that can replicate in the animal host, not including diseases caused by toxins or venoms. Regarding the transmissibility, zoonoses are considered those diseases that can be transmitted from animal to humans via an insect vector or via direct contact with the animal or its products [2]. Zoonotic infections can be transmitted to humans through many routes, the most common being animal bites and scratches, contaminated animal food products, through work exposure such as in jobs such as veterinarians or farmers, arthropods as vectors or contaminated soil and watercourses.
Zoonoses can be caused by many pathogens, such as viruses, bacteria, parasites and prions.
Globalization has guaranteed an easier route for some pathogens to transmit and the continuous flow of people traveling the world has exposed a large number of humans to many different cultural and alimentary customs, previously restricted to a small area. A growing number of microbes have jumped from their usual reservoir and have become able to infect humans [3,4,5].
The most recent example of this natural process, defined as “spillover”, is the jump of SARS-CoV-2 from mammals to humans in 2019, which led to a pandemic [6].
Among all the animals causing known and emerging zoonoses, bats have been under observation as one of the main reservoirs for viruses. Even though it is impossible to calculate the risk of a specific virus to spill over, it has been observed that RNA viruses are most likely to jump between species, as the Ebola epidemic and SARS-CoV-2 pandemic demonstrate [7].
Due to SARS-CoV-2 disruption, many infectious disease diagnoses, such as tuberculosis, have been delayed [8]. Among these, HIV testing and thus diagnosis have slowed down and a spread of new infections is being observed globally, with many tardive diagnoses, formulated after casual discovery of cancers or other acquired immunodeficiency syndrome (AIDS)-defining illnesses [9]. Meanwhile, the number of zoonotic diseases in many areas is still a public health problem.
Zoonotic infections, such as brucellosis, echinococcosis, leishmaniasis, rabies and zoonotic salmonellosis are very common in the Mediterranean area. In 1978, the Mediterranean Zoonoses Control Center (MZCC) was established. The main reason behind the great spread of zoonoses in the Mediterranean area is the favorable climate for mosquitos and other kinds of arthropods. Therefore, the Mediterranean area can be defined as a hotspot for the development and transmission of most common zoonotic infections. The control over the environment and the local animal species has limited the spread of these kinds of diseases, while the Middle East and the African regions have become a matter of concern for emerging infectious diseases. However, the diseases transmitted by animals, such as brucellosis, rickettsiosis, and leishmaniasis, are still a strong component of the infectious diseases diagnoses in the Mediterranean area [10].
The immune-deficiency due to HIV infection is a major risk factor, not only for the development of cancers [11,12,13,14,15,16,17,18,19,20], but also for other infectious diseases defined as “opportunistic”. Some of them are characteristic of the AIDS stage of HIV infection and well known from the pre-antiretroviral therapy (ART) period; those are what we call AIDS-defining illnesses.
Meanwhile, infections in people living with HIV (PLWH) by other bacteria, not considered characteristic of HIV infection, are not so rare [21]. The presence of an HIV reservoir in T-cells of PLWH under ART [22] may lead to a different response from the immune system to common zoonoses, especially the ones that usually elicit a T-cell based response. The ART itself, by affecting the underlying inflammation by various mechanisms [23], may be related to a different kind of response of PLWH to some zoonoses.
We decided to analyze the more neglected zoonoses, typical of the Mediterranean area, in relation to HIV.

2. Epidemiology

According to the OneHealth report from the European Centre for Disease Prevention and Control (ECDC) and the European Food Safety Authority (EFSA), in 2020, campylobacteriosis has been confirmed to be the most frequent zoonosis in the European Union region, accounting for 60% of zoonotic disease diagnoses with 120,946 cases (Table 1). The following most prevalent zoonoses are salmonellosis, yersioniosis, infections by shiga toxin-producing Escherichia coli (STEC) and listeriosis. In the same year, there were 641 cases of tularemia, and also Coxiella burnetii infection, even if sporadic outbreaks associated with contaminated waters and mosquito’s bites were reported [24]. Echinococcosis covered for a grand total of 488 cases in Europe in 2020, and cystic echinococcosis has an annual incidence from <1 to 200 per 100,00 in endemic areas, such as western China, Central Asia, South America, Mediterranean countries and eastern Africa [25]. In 2020, brucellosis was accountable for 128 new diagnoses in the European regions. According to the OneHealth report and ECDC data between 2016 and 2020, a significant reduction in the incidence of brucellosis diagnoses has been observed in European countries, even if it remains endemic in specific areas including the Mediterranean basin, the Middle East, the Indian subcontinent, Latin America and some African countries [26].
Regarding HIV infections, according to World Health Organization (WHO) data, there were an estimated 37.7 million PLWH at the end of 2020, with 1.5 million new diagnoses in 2020, and 104,765 in 46 out of 53 of the European regions that belong to the WHO Europe.

3. Campylobacteriosis

Campylobacter is a genus of bacteria of the family Campylobacteraceae and, to date, comprehends a total of 32 species and 9 subspecies. The most common is C. jejuni, and to a lesser extent, C. coli.
In a systematic review published in 2021 on campylobacteriosis in the sub-Saharan African regions by Hlashwayo et al. [27], campylobacteriosis was found to have no difference in prevalence in HIV-infected and non-HIV-infected patients, while a higher prevalence was found in the HIV group with diarrhea compared to the ones with no diarrhea. This data confirmed the findings of a previous study on gastroenteritis in 235 MSM in 2017–2018 by Newman et al. [28], with 148 of them being seropositive and with no differences in Campylobacter detection between the HIV and non-HIV groups.
Infection by Campylobacter occurs mostly by injection of Campylobacter-contaminated raw or undercooked meat, raw milk, tap water and various chicken-containing dishes. The motility of the bacterium is granted by the flagella, which are fundamental for colonization. Adhesion to the intestinal epithelium is mediated by some proteins present on the Campylobacter surface, such as CapA or the protein of Campylobacter adhesion, and the cell damage is brought about by the production of cytotoxins [29]. Campylobacteriosis usually involves a self-limiting gastroenteritis, clinically characterized by fever and vomit that may last from one to three days, abdominal pain and diarrhea that may last up to two weeks [30,31].
In many studies, prior to the introduction of ART, a more severe campylobacteriosis is described, demonstrating that the antiretroviral therapy has impacted infections by Campylobacter in PLWH in many ways [32].
In a study by Larsen et al. (2011) [33], it was found that the incidence of Campylobacter-related diseases in PLWH in Denmark has decreased since the introduction of the ART; in the same study, however, an increase in campylobacteriosis in men who have sex with men (MSM) was also observed.
In a study conducted in Ghana by Forson et al. [34], where the Campylobacter-associated gastroenteritis in hospitalized PLWH was evaluated, a high prevalence of C. coli was found in the population, with also a significant percentage of resistance genes. Other evidence in the literature report Campylobacter to be the most common pathogen associated with diarrhea in PLWH as well [35,36,37], such as in a study conducted by Samie et al. [38], in which Campylobacter was proved to be the most common pathogen associated with diarrhea in HIV-infected individuals with a percentage of 22.8%. Similar results were obtained in a study of 215 HIV patients in Ethiopia, where Campylobacter was confirmed to be the most common pathogen causing gastroenteritis (6.04%) [39], and in another study with a prevalence of 4.4% [40].
While Campylobacter is usually associated with gastrointestinal symptoms, generally self-limiting, there are cases of Campylobacter-related bacteremia reported in the literature. In 1998, the relation between Campylobacter bacteremia in 21 PLWH was analyzed by Tee w et al. [41], and the disease was found to be significantly more severe than in non-immunocompromised people, with a mortality rate of 33%. In a study by Fernandez-Cruz et al. [42], Campylobacter bacteremia was found to be more severe in HIV-infected patients compared to non-HIV-infected (33% vs. 10%), although it has to be said that the higher prevalence of Campylobacter bacteremia in HIV-infected people was chronologically located in the pre-ART era. Particular cases include the one of a cellulitis consequent to Campylobacter bacteremia in a HIV patient, which recovered after antibiotic therapy [43], and a case of bacteremia from Campylobacter jejuni in an HIV-infected patient at the AIDS stage [44].
The increasing resistance of Campylobacter to specific classes of antibiotics, however, has raised concern for this normally self-limiting zoonosis. Some genes have been reported to be associated with aminoglycosides and macrolides resistance, and the efflux pump CmeABC variant is the culprit for increasingly high doses of fluoroquinolones resistance [45]. The emergence of erm(B), instead, is related to high-level macrolide resistance [46].
Campylobacter levels are often altered in the gut microbiota in many different diseases [47,48].
In a study conducted in Nigeria by Nowak et al. [49], three populations of MSM were compared: the HIV uninfected, the untreated seropositive people, and the HIV-infected who were receiving ART. Notably there were no differences in Campylobacter levels in the microbiome in the first two groups; meanwhile, in PLWH under ART, a significant increase in Campylobacter population was found in rectal microbiota.
Significantly, a higher prevalence of Campylobacter in PLWH under ART was already proved by a prior study published in 2014 by Li Y et al. [50] in another anatomical region and in different human fluids: the concentration of Campylobacter was higher in the saliva of HIV-infected patients who were taking ART.
Meanwhile, in a study by Wells et al. [51] conducted in 50 female patients with HIV and high-risk but without HIV infection, there was no significant difference in anal microbiome concerning the presence of Campylobacter. In an analysis conducted on the microbiomes of 383 MSM by Cook et al. [52], comparing HIV-infected with undetectable titer, non-HIV and viremic HIV, Campylobacter was found to be decreased in the microbiome of HIV-infected suppressed patients, while it was instead increased in viremic HIV-infected. Similar results were given in a study on the lingual microbiome in untreated HIV people by Dang et al. [53].
Peculiar cases with atypical clinical presentation are reported by Rajendran et al. [54], describing erythematous plaques by Campylobacter in a seropositive patient, aortitis by C. fetus in an HIV-infected man [55], spondylodiscitis caused by C. fetus [56] and persistent diarrhea in an HIV + person with the first isolation of C. infans [57].

4. Salmonellosis

Salmonella is a Gram-negative rods genus belonging to the Enterobacteriaceae family. The most known serotypes belonging to Salmonella spp. are S. typhi and S. paratyphi, which cause enteric fever. Less known, but still responsible for over 1 million infections per year in the US, is the non-typhi Salmonella [58].
Salmonellosis is usually contracted through the consumption of contaminated food, mostly eggs, meat, poultry and milk that have not been properly cooked. In 2022, a red flag was put on peanut butter for the increasing number of cases of Salmonellosis. Transmission person-to-person is also possible through the fecal-oral route, and humans can contract Salmonellosis also via contact with domestic or not domestic pets.
Salmonellosis is usually characterized by the onset of fever, abdominal pain, diarrhea, nausea and vomiting. The symptoms usually occur 6–72 h after ingestion of Salmonella and can last up to 7 days. They are usually mild and self-limiting, even if in some more fragile patients they can be more severe. Other than the most common manifestations, there have been particular cases of Salmonella-related liver abscesses in HIV-infected patients [59,60,61], Salmonella meningitides [62,63] and thyroiditis due to Salmonella in PLWH [64].
Despite being usually self-limiting in immunocompetent people, it has been demonstrated that PLWH are at major risk of developing bloodstream infection, so much so that recurrent salmonella septicemias have been recognized as an AIDS-defining illness. In particular, those with invasive infections by non-typhi Salmonella (iNTS) are the ones at risk of a more severe prognosis [65], especially PLWH not on ART regimen [66]. This is confirmed by the analysis conducted on PLWH and the risk of recurrent non-typhoid salmonellosis by Hung CC et al. [67], which appeared to be reduced after the introduction of ART [68].
In particular, iNTS are a prominent issue in severely immunocompromised HIV-infected people (commonly identified with CD4+ count < 200 cell/uL) in African regions [69,70,71,72,73,74,75,76], often recognized as the cause of a severe bacteremia [77,78]. The severity of the iNTS has caused an epidemic, mostly because of the antibiotic resistance that has raised concern in recent years. In particular, some specific variants of S. typhimurium have developed mechanisms of multidrug resistance as a phase 2 flagellum [79]; meanwhile, S. typhi seems to have maintained sensibility to commonly used antibiotics [80,81,82]. In a study by Crump et al., HIV seemed to even have a protective role against typhoid fever [83].
The severity of iNTS in PLWH may be due to an impaired immune response to the infection, as suggested in a study by MacLennan et al. [84]; specifically, it was reported that an excess of antibodies against Salmonella lipopolysaccharide (LPS) is associated with a reduction in Salmonella killing. Other reasons behind the severity of iNTS in PLWH may be found in the dysregulation of proinflammatory cytokine release, such as TNF alpha, IL-10 and IL-12 [85], the attenuation of transcription factor nuclear κB (NFκB)-mediated inflammation [86], the defective activity of monocytes phagocytosis [87] and the apparent enhanced capacity of a specific sequence type 313 (ST313) of S. typhimurium of surviving in HIV-infected macrophages and their defective phagocytic ability [88,89].
An interesting study by Dandekar et al. [90] suggests that the depletion of the subset Th17 of CD4 T-helper cells in the gut impairs the immune response in the mucosa, leading to translocation of bacteria such as S. typhimurium and its consequent invasive infection.
Introduction of ART has modified radically the history of salmonellosis in HIV-infected people.

5. Listeriosis

Listeria monocytogenes is an anaerobic bacterium that can contaminate many different kinds of food, such as milk, meat and vegetables. It has the unique capability to infect the fetoplacental system and this makes listeriosis a not so rare disease among newborns and pregnant women. A concerning outbreak of listeriosis has been reported in South Africa by Thomas et al. [91], probably related to polony, a processed meat; in 38% of the pregnancy associated cases, the patients were seropositive, as well as in 46% of the non-pregnancy associated cases.
Listeria has various virulence factors, such as Internalin A and B, which can facilitate the cell’s invasion. Bacteremia and neurolisteriosis, in particular meningitidis, are the most common expression of Listeria infection [92].
Since the discovery of HIV and the opportunistic AIDS-related infections in late 1980s, there have been several cases of listeriosis in PLWH [93,94], and the most common manifestation was meningitis [95,96].
Despite remaining infrequent, as opportunistic infection, few cases of Listeria-related meningitis have been reported in PLWH, even after the introduction of ART [97,98,99,100]; sometimes listeriosis led to further examinations and diagnosis of HIV [101,102]. Few cases of bacteremia have been reported as well [103,104].
In a study conducted on pregnant women in Brazil by Freitag et al. [105], seroprevalence for Listeria was found to be associated with HIV; on the other hand, no association with HIV and prevalence of Listeria in feces was found in another study by the same authors [106].
Atypical manifestations of listeriosis in PLWH include aortic aneurysm [107], peritonitis [108], prostatitis [109] and a case of cholecystitis and sepsis [110].

6. Echinococcosis

Echinococcus is a globally distributed parasite. The main species of Echinococcus are E. granulosus, which cause cystic echinococcosis (CE), diffused throughout Africa, Europe, Asia, the Middle East, Central and South America, and E. multilocularis, which causes alveolar echinococcosis (AE), prevalent in the northern latitudes of Europe, Asia, and North America. According to ECDC reports, in 2020, 529 confirmed echinococcosis cases were reported in the European Union. Among these, 243 cases were reported as Echinococcus granulosus, 114 as Echinococcus multilocularis, and 172 were reported as unknown species. The European Register of CE (ERCE) is a platform originated in 2014, with 15 countries (7 not European) affiliated to it, with the purpose of showing that CE is a relevant issue for public health. Since its foundation, 3386 cysts have been recorded at first registration [111].
The diffusion of echinococcosis is related to dogs, in which the cysts develop into adult tapeworms. Tapeworm’s eggs are diffused in the ground through the dog’s feces and animals can get infected by ingesting them. Humans get the infection usually by consumption of infected water, soil or food.
CE usually remains asymptomatic until the hydatid cysts grow large enough to provoke nausea, discomfort and pain. It may take several years to become symptomatic. The cysts can usually be found in the liver and lungs. CE is associated with polyfunctional T-cell subsets (as IL-2+TNF-α+Th2+ triple-positive and TNF-α+Th2+ double-positive T-cells) related to cyst biological activity [112].
In AE, E. multilocularis do not fully develop as cysts; rather, it generally causes vesicles in the liver and may diffuse to other organs.
Notably, in a study by Wahlers et al. [113,114], it was hypothesized that HIV and/or tuberculosis infection may orient the host’s immune response towards Th-2, and Th-2 response was demonstrated to have an association with active CE and resistance to albendazole treatment.
However, to date, there is no strong evidence of a correlation between HIV and echinococcosis, mostly being cases of sporadic infection by Echinococcus in PLWH.
There are no studies concerning echinococcosis in PLWH in the Mediterranean area. However, in a study conducted in Mozambique, the prevalence of parasitosis among PLWH has been evaluated: echinococcosis accounted for 17.3% of the overall prevalence [115]. More recently, the prevalence of echinococcosis in immunocompromised patients has been evaluated in a review by Ghasemirad et al. [116], and HIV resulted in the most common condition in CE.
The vast majority of cases reported in the literature concerning infection of CE in PLWH confirms this data [117,118,119,120,121,122,123]: most of them had a full recovery after treatment. There are two cases of AE in seropositive patients [124,125], and a case of Echinococcus vogeli, causing polycystic echinococcosis [126].
Therefore, there seems to be a prevalence of CE among PLWH affected by echinococcosis, but HIV infection does not seem to affect the prognosis of echinococcosis. Further studies are needed to evaluate a possible relationship.

7. Brucellosis

Brucellosis is a bacterial infection usually transmitted by the consumption of raw meat or dairy products of infected animals. Other routes of infection are through the conjunctiva, respiratory tract or abraded skin. Symptoms of the infections are various and mostly nonspecific, such as fatigue and fever. Sweating with a strong odor is characteristic, but not always present. Hepatomegaly and splenomegaly can also occur. A frequent complication is osteoarticular compromise.
The most important species of Brucella for human health are B. melitensis, B. abortus and B. suis; B. canis is of less importance.
There is no strong association between brucellosis and HIV, and we did not find studies concerning brucellosis in PLWH in the Mediterranean regions. However, there are reports of brucellosis in specific settings that suggest a higher prevalence than expected. In a review conducted by Khademi et al. [127] on bacterial infections in hospitalized Iranian PLWH up to 2017, brucellosis was estimated to account for 26.3% of an overall rate of 48.6% of bacterial coinfections. Earlier in 2010, 90 seropositive patients were confronted with 100 controls in an Iranian cohort: the seroprevalence of brucellosis was significantly higher in PLWH than the controls, with a percentage of 73.3% vs. 30% [128]. In 2011, the prevalence of Brucella antibodies titer in 184 HIV-infected patients was assessed to be 6% (11 patients), with only three of them being symptomatic [129].
In Malawi, a sub-Saharan area, the prevalence of brucellosis among pregnant seropositive women was evaluated: 5 out of 201 (2.48%) had positive serology for Brucella and no symptoms, compatible with a previous infection [130].
Brucellosis seroprevalence was also assessed in Kenya, after the report of two patients with HIV and a serology positive for Brucella: among 100 patients, 65 of them being PLWH, 21 patients had IgG-serology for Brucella, 6 of them had IgM only, and 8 of them had both IgM and IgG, showing a rather significant prevalence of antibodies for Brucella [131].
About seven cases of brucellosis in PLWH are reported in the literature; most of them had complete recovery after diagnosis and opportune treatment [132,133,134,135,136,137].
In a small cohort of people of a case series reported by Moreno et al. [138], 12 people with HIV were diagnosed with brucellosis, mostly presenting the same clinical manifestation. In 11 of them, a common origin for the infection was identified.
HIV infection does not seem to affect Brucella prevalence, even though in endemic countries the incidence of brucellosis in PLWH is higher than expected; therefore, it is important to consider diagnosis of brucellosis in some specific geographic area and maintain attention on how it could affect immunocompromised people.

8. Rickettsiosis

Rickettsia is a group of obligate intracellular bacteria, widely distributed throughout the world. Rickettsiosis is divided into two main groups: the spotted fever group, transmitted by ticks or mites, and the typhus group, mainly transmitted by lice or fleas, and which comprehend Rickettsia typhi and Rickettsia prowazekii. Rickettsia conorii is one of the prevalent species in the Mediterranean area, causing the Mediterranean spotted fever, and it is usually associated with domestic pets.
Rickettsia infection usually leads to an increased vascular permeability and release of tumor necrosis factor alpha (TNF-alpha). Local rickettsiosis can be identified by a characteristic eschar with a necrotizing base. Disseminated rickettsiosis may lead to severe vasculitis, pneumonitis, meningoencephalitis and multiorgan failure. Nonspecific symptoms are fever, lymphadenopathy and diffused rash [139].
There is no strict association between rickettsiosis and HIV, as demonstrated by studies where seroprevalence for Rickettsia did not differ between the HIV group and the non-HIV group [140,141]. In a study in northeastern Spain, among 341 seropositive patients, 4.4% had positive serology for R. felis and 7.6% were seroreactive for R. typhi. Three patients had antibodies for both species [142].
There are three other cases, to our knowledge, of rickettsiosis in seropositive patients: a case of Mediterranean spotted fever, a case of rickettsialpox caused by R. akari, and a case of bilateral cilioretinal artery occlusion and uveitis in an HIV patient seroreactive for Toxoplasma and Rickettsia [142,143,144,145].
To date, Rickettsia does not seem to pose a threat for PLWH greater than that for the non-HIV-infected population, but it has to be considered among the possible diagnoses when clinically suggestive.

9. Borreliosis

A complex of spirochete bacteria, collectively known as Borrelia burgdoferi, is the cause of Lyme disease. Lyme disease is the most common vector borne disease in the United States and is also very prevalent in Europe. Borreliosis is transmitted by the bite of ticks that have been previously infected by biting other mammals. The characteristic skin lesion of Lyme disease is the erythema migrans, consisting of two concentric circular erythematous lesions. If the bacterium diffuses to other organs, it may cause alterations at the central nervous system (CNS), heart or joints [146,147].
Interestingly, a greater prevalence for IgM of Borrelia was demonstrated in the HIV group, with 227 patients, rather than the non-HIV group, in the same study where the seroprevalence for Rickettsia was tested [140]. Specifically, seroprevalence for IgM was 29.1%, and IgG, 4.8%.
In the literature, we found 13 cases of borreliosis in PLWH patients, most of them with a very similar presentation and course to the non-HIV-infected patients, and mostly presenting with cutaneous and/or neurological manifestations [148,149,150,151,152,153,154,155,156]. A woman undergoing treatment with ART had severe neurological sequelae after being treated for neuroborreliosis, and deambulation was especially compromised [157]. An atypical case was reported by Bratzke et al. [158], in which a patient with HIV was infected with Borrelia and developed a pseudolymphoma with unusual cytological features, lacking T-helper and Langerhans cells, but with an increased number of cytotoxic cells.
The correlation between Borrelia and HIV, or eventual complications of both infections, is unclear. In a study concerning depression and suicidal thoughts among patients with a history of Lyme disease in HIV and non-HIV patients, there was no significant difference in depression and development of suicidal thought between the two groups [159].
However, interestingly, the use of CXCL13 in the cerebrospinal fluid was suggested as a marker for neuroborreliosis, in comparison to other neurological infectious diseases. It was found that the protein levels decreased after treatment for borreliosis, but the marker levels were found elevated in 52% of the HIV untreated and neurologically asymptomatic patients, even considering that there was an overlap in the two groups [160]. Therefore, while a correlation between the two infectious diseases is still unclear, it seems that there are similar patterns mostly concerning neurological and psychiatric complications, such as depression, and biochemical markers.

10. Leishmaniasis

Leishmaniasis is a zoonosis caused by protozoan parasites, transmitted by the bite of infected female phlebotomine sandflies. Clinically, there are two forms of leishmaniasis: visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL) [161]. Leishmania infantum causes both visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL), and is endemic in the entire Mediterranean basin, while Leishmania major and Leishmania tropica causing CL are present only in countries of northern Africa and in Azerbaijan. Meanwhile, L. donovani sensu stricto has been found in certain areas of Cyprus and Turkey.
Leishmania and HIV coinfection was an emerging problem in the Mediterranean area during the 1990s, especially concerning Italy, Portugal, France and Spain. The introduction of ART has modified the history of this coinfection, achieving a 50–60% reduction in VL incidence [162]. A high incidence, especially in Spain, of Leishmania/HIV coinfection suggests that HIV infection might pose a risk for leishmaniasis and vice versa [163]. It has been shown that detectable peripheral blood parasitemia is more frequent in PLWH than in not-HIV-infected people [164]. Typical features of VL are fever, weight loss, hepatosplenomegaly and pancytopenia. Having common and non-specific features, acute visceral leishmaniasis may mask a primary HIV infection or, sometimes, reveal it [165]. Cutaneous involvement seems to be infrequent in HIV/Leishmania coinfected people. Meanwhile, sometimes, the inspection for skin lesions in PLWH, thought to be Kaposi Sarcoma, revealed cutaneous manifestation of Leishmania [166]. The severity of leishmaniasis in PLWH may be related to the shift towards a T helper 2 (Th2)-type specific response, instead of T helper 1, an amplification in NF-κB activation, and changes in CXCR4/CCR5 surface expression [167,168,169]. On the contrary, leishmaniasis seems to also affect and favor HIV progression to AIDS stage, accelerating the viral replication [170].
The interactions between the two infections constitute a major risk factor, not only for the severity of both diseases, but also for leishmaniasis reactivations, especially in people with a CD4+ count < 200 cell/uL [171].
Amphotericin B remains the first line option, with antimonials as the second line, even though lower efficacy of leishmaniasis treatment has been demonstrated in PLWH, with an impaired viro-immunological status [172]. The efficacy of secondary prophylaxis in PLWH is controversial, despite many studies having been conducted in the Mediterranean regions, mostly with amphotericin B lipid complex and liposomal amphotericin B [162].

11. Monkeypox

The emerging number of cases of monkeypox in European countries has brought renewed attention to this disease, which was originally isolated in humans in 1970. Monkeypox is a zoonotic disease caused by an orthopoxvirus, resulting in a smallpox-like disease in humans. Since its first isolation, monkeypox has become endemic in the Democratic Republic of Congo (DRC) and other African regions. In addition, the median age has varied over the years, from young children to young adults, probably due to the cessation of smallpox vaccination, which probably also provided some sort of protection against monkeypox.
Initial symptoms include fever, fatigue and headache. Generalized lymphadenopathy, mostly in maxillary, cervical and inguinal regions is typical, along with a rash, first macular, then papular, then vesicular and pustular, which appears first on the head region and then diffuses in other parts of the body with centrifugal distribution [173].
Among cases with known HIV status in EU countries and up to July 2022, 40% (364/917) were HIV-infected. A specific case of monkeypox in a HIV patient has been reported in the literature: a male in his 30s, viro-suppressed and with a CD4+ count above 700 cells/uL, had genital rash, with no other initial symptoms. He then developed malaise and fever and the rash diffused on the rest of the body. He was admitted to hospital and started on antibiotics. The man’s condition improved, and he was discharged [174]. Even if the infection did not seem to have any sequelae, the risk of uncontrolled HIV infection may be a major risk factor for the increasing number of monkeypox cases. Moreover, in the case described, the infection was sexually transmitted, so unsafe sexual behavior has to be considered a major concern not only for HIV and other sexually transmitted diseases (STD), but for monkeypox too.

12. Conclusions

It is known that HIV infection in the absence of ART causes immunodeficiency that may lead to opportunistic infections from neglected pathogens, which normally, in an immunocompetent person, do not cause severe disease. In some cases, as in the case of Salmonella, the infection was recognized as an AIDS-defining illness. In other cases, there does not seem to be a strong correlation with HIV. The introduction of ART has surely changed the odds, and pathogens such as Campylobacter are no longer more virulent than they are in immunocompetent people. However, as observed, in PLWH under ART, there are alterations in the microbiome for these pathogens or overlapping symptoms, as in the case of neuroborreliosis. Thus, even if the epidemiology of the most common zoonoses in the Mediterranean do not seem to have a strict relationship with HIV, they have to be kept in mind when formulating a diagnosis, as well as the possible consequences. Further studies are needed to explore a possible interaction between these important infectious diseases.

Author Contributions

Conceptualization, Y.R. and C.M.; writing—original draft preparation, Y.R.; writing—review and editing, E.V.R. and G.F.P.; supervision, G.N. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hahn, B.H.; Shaw, G.M.; De Cock, K.M.; Sharp, P.M. AIDS as a Zoonosis: Scientific and Public Health Implications. Science 2000, 287, 607–614. [Google Scholar] [CrossRef] [PubMed]
  2. Chomel, B. Zoonoses. In Encyclopedia of Microbiology, 3rd ed.; Elsevier: Amsterdam, The Netherlands, 2009; pp. 820–829. [Google Scholar]
  3. Bezerra-Santos, M.A.; Mendoza-Roldan, J.A.; Thompson, R.A.; Dantas-Torres, F.; Otranto, D. Illegal Wildlife Trade: A Gateway to Zoonotic Infectious Diseases. Trends Parasitol. 2021, 37, 181–184. [Google Scholar] [CrossRef] [PubMed]
  4. Moutou, F. Zoonoses infectieuses: Risques liés à la faune sauvage. Rev. Prat. 2019, 69, 333–335. [Google Scholar] [PubMed]
  5. Maeda, K. Ken. Globalization and zoonosis. Nihon Rinsho Jpn. J. Clin. Med. 2016, 74, 1948–1955. [Google Scholar]
  6. Lytras, S.; Xia, W.; Hughes, J.; Jiang, X.; Robertson, D.L. The animal origin of SARS-CoV-2. Science 2021, 373, 968–970. [Google Scholar] [CrossRef]
  7. Wang, L.-F.; Anderson, D.E. Viruses in bats and potential spillover to animals and humans. Curr. Opin. Virol. 2019, 34, 79–89. [Google Scholar] [CrossRef]
  8. Migliori, G.B.; Thong, P.M.; Akkerman, O.; Alffenaar, J.-W.; Álvarez-Navascués, F.; Assao-Neino, M.M.; Bernard, P.V.; Biala, J.S.; Blanc, F.-X.; Bogorodskaya, E.M.; et al. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. Emerg. Infect. Dis. 2020, 26, 2709–2712. [Google Scholar] [CrossRef]
  9. Micali, C.; Russotto, Y.; Facciolà, A.; Marino, A.; Celesia, B.M.; Pistarà, E.; Caci, G.; Nunnari, G.; Pellicanò, G.F.; Rullo, E.V. Pulmonary Kaposi Sarcoma without Respiratory Symptoms and Skin Lesions in an HIV-Naïve Patient: A Case Report and Literature Review. Infect. Dis. Rep. 2022, 14, 228–242. [Google Scholar] [CrossRef]
  10. Morse, S.S.; Mazet, J.A.; Woolhouse, M.; Parrish, C.R.; Carroll, D.; Karesh, W.B.; Zambrana-Torrelio, C.; Lipkin, W.I.; Daszak, P. Prediction and prevention of the next pandemic zoonosis. Lancet 2012, 380, 1956–1965. [Google Scholar] [CrossRef]
  11. Micali, C.; Russotto, Y.; Caci, G.; Ceccarelli, M.; Marino, A.; Celesia, B.M.; Pellicanò, G.F.; Nunnari, G.; Rullo, E.V. Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV. Infect. Dis. Rep. 2022, 14, 43–55. [Google Scholar] [CrossRef]
  12. Facciolà, A.; Rullo, E.V.; Ceccarelli, M.; D’Andrea, F.; Coco, M.; Micali, C.; Cacopardo, B.; Marino, A.; Cannavò, S.P.; Di Rosa, M.; et al. Malignant melanoma in HIV: Epidemiology, pathogenesis, and management. Dermatol. Ther. 2020, 33, e13180. [Google Scholar] [CrossRef] [PubMed]
  13. d’Aleo, F.; Ceccarelli, M.; Venanzi Rullo, E.; Facciolà, A.; d’Andrea, F.; Micali, C.; Coco, M.; Pinzone, M.R.; Focà, E.; Condorelli, F.; et al. Anal cancer in people living with HIV: The importance of the screening and of early diagnosis. World Cancer Res. J. 2019, 6, e1319. [Google Scholar] [CrossRef]
  14. D’Andrea, F.; Pellicanò, G.F.; Venanzi Rullo, E.; d’Aleo, F.; Facciolà, A.; Micali, C.; Coco, M.; Visalli, G.; Picerno, I.; Condorelli, F.; et al. Cervical cancer in women living with HIV: A review of the literature. World Cancer Res. J. 2019, 6, e1224. [Google Scholar]
  15. d’Aleo, F.; Cama, B.A.V.; Paolucci, I.A.; Venanzi Rullo, E.; Condorelli, F.; Facciolà, A.; Di Francia, R.; Savasta, A.; Pinzone, M.R.; Picerno, I.; et al. New and old assumptions on lung cancer in people living with HIV. World Cancer Res. J. 2018, 5, e1036. [Google Scholar] [CrossRef]
  16. D’Andrea, F.; Ceccarelli, M.; Rullo, E.V.; Facciolà, A.; d’Aleo, F.; Cacopardo, B.; Iacobello, C.; Costa, A.; Altavilla, G.; Pellicanò, G.F.; et al. Cancer screening in HIV-infected patients: Early diagnosis in a high-risk population. World Cancer Res. J. 2018, 5, e1130. [Google Scholar] [CrossRef]
  17. Ceccarelli, M.; Condorelli, F.; Venanzi Rullo, E.; Pellicanò, G.F. Editorial—Improving access and adherence to screening tests for cancers: A new, though old, challenge in the HIV epidemics. World Cancer Res. J. 2018, 5, e1030. [Google Scholar] [CrossRef]
  18. D’Andrea, F.; Ceccarelli, M.; Facciolà, A.; Nunnari, G.; Pellicanò, G.F.; Venanzi Rullo, E. Breast cancer in women living with HIV. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 1158–1164. [Google Scholar] [CrossRef] [PubMed]
  19. Facciolà, A.; Ceccarelli, M.; Venanzi Rullo, E.; d’Aleo, F.; Condorelli, F.; Visalli, G.; Cacopardo, B.; Pinzone, M.R.; di Rosa, M.; Nunnari, G.; et al. Prostate cancer in HIV-positive patients: A review of the literature. World Cancer Res. J. 2018, 5, e1136. [Google Scholar] [CrossRef]
  20. Facciolà, A.; Venanzi Rullo, E.; Ceccarelli, M.; d’Aleo, F.; D’Andrea, F.; Visalli, G.; Pinzone, M.R.; Picerno, I.; Cacopardo, B.; Condorelli, F.; et al. Hodgkin’s lymphoma in people living with HIV: Epidemiology and clinical management. World Cancer Res. J. 2019, 6, e1295. [Google Scholar] [CrossRef]
  21. Pistarà, E.; Marino, A.; Ceccarelli, M.; Cosentino, F.; Moscatt, V.; Gussio, M.; Micali, C.; Nunnari, G.; Cacopardo, B.; Celesia, B.M. HIV Infection Diagnosis in a Late Presenter Patient during a Severe Imported Falciparum Malaria: A Challenging. Open Access Maced. J. Med. Sci. 2022, 10, 103–106. [Google Scholar] [CrossRef]
  22. Rullo, E.V.; Pinzone, M.R.; Cannon, L.; Weissman, S.; Ceccarelli, M.; Zurakowski, R.; Nunnari, G.; O’Doherty, U. Persistence of an intact HIV reservoir in phenotypically naive T cells. JCI Insight 2020, 5, e133157. [Google Scholar] [CrossRef] [PubMed]
  23. Pinzone, M.R.; Ceccarelli, M.; Rullo, E.V.; Maresca, M.; Bruno, R.; Condorelli, F.; Di Rosa, M.; Madeddu, G.; Foca’, E.; Calcagno, A.; et al. Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease. Biomed. Rep. 2019, 10, 140–144. [Google Scholar] [CrossRef] [PubMed]
  24. Hennebique, A.; Boisset, S.; Maurin, M. Tularemia as a waterborne disease: A review. Emerg. Microbes Infect. 2019, 8, 1027–1042. [Google Scholar] [CrossRef] [PubMed]
  25. Wen, H.; Vuitton, L.; Tuxun, T.; Li, J.; Vuitton, D.A.; Zhang, W.; McManus, D.P. Echinococcosis: Advances in the 21st Century. Clin. Microbiol. Rev. 2019, 32, e00075-18. [Google Scholar] [CrossRef] [PubMed]
  26. Yagupsky, P.; Morata, P.; Colmenero, J.D. Laboratory Diagnosis of Human Brucellosis. Clin. Microbiol. Rev. 2019, 33, e00073-19. [Google Scholar] [CrossRef] [PubMed]
  27. Hlashwayo, D.F.; Sigaúque, B.; Noormahomed, E.V.; Afonso, S.M.S.; Mandomando, I.M.; Bila, C.G. A systematic review and meta-analysis reveal that Campylobacter spp. and antibiotic resistance are widespread in humans in sub-Saharan Africa. PLoS ONE 2021, 16, e0245951. [Google Scholar] [CrossRef]
  28. Newman, K.L.; Newman, G.S.; Cybulski, R.J.; Fang, F.C. Gastroenteritis in Men Who Have Sex with Men in Seattle, Washington, 2017–2018. Clin. Infect. Dis. 2019, 71, 109–115. [Google Scholar] [CrossRef]
  29. Facciolà, A.; Riso, R.; Avventuroso, E.; Visalli, G.; Delia, S.A.; Laganà, P. Campylobacter: From microbiology to prevention. J. Prev. Med. Hyg. 2017, 58, E79–E92. [Google Scholar]
  30. Kim, S.-H.; Chelliah, R.; Ramakrishnan, S.R.; Perumal, A.S.; Bang, W.-S.; Rubab, M.; Daliri, E.B.-M.; Barathikannan, K.; Elahi, F.; Park, E.; et al. Review on Stress Tolerance in Campylobacter jejuni. Front. Cell. Infect. Microbiol. 2021, 10, 596570. [Google Scholar] [CrossRef]
  31. Costa, D.; Iraola, G. Pathogenomics of Emerging Campylobacter Species. Clin. Microbiol. Rev. 2019, 32, e00072-18. [Google Scholar] [CrossRef]
  32. Manfredi, R.; Calza, L.; Chiodo, F. Enteric and disseminated campylobacter species infection during HIV disease: A persisting but significantly modified association in the HAART era. Am. J. Gastroenterol. 2002, 97, 510–511. [Google Scholar] [CrossRef] [PubMed]
  33. Larsen, I.K.; Gradel, K.O.; Helms, M.; Hornstrup, M.K.; Jürgens, G.; Mens, H.; Rosager, C.L.; Clausen, T.H.; Kronborg, G.; Nielsen, H. Non-typhoidal Salmonella and Campylobacter infections among HIV-positive patients in Denmark. Scand. J. Infect. Dis. 2010, 43, 3–7. [Google Scholar] [CrossRef] [PubMed]
  34. Forson, A.O.; Adjei, D.N.; Olu-Taiwo, M.; Quarchie, M.N.; Asmah, H.R. Characterization of Campylobacter associated gastric enteritis among patients with Human Immunodeficiency Virus (HIV) in a hospital in Accra, Ghana. PLoS ONE 2020, 15, e0240242. [Google Scholar] [CrossRef] [PubMed]
  35. Vizzi, E.; Angulo Medina, L.A. Agentes patógenos responsables de trastornos gastrointestinales en sujetos infectados con VIH [Enteropathogens responsible for gastrointestinal disorders in HIV patients]. Investig. Clín. 2013, 54, 90–108. [Google Scholar]
  36. Bhaijee, F.; Subramony, C.; Tang, S.-J.; Pepper, D.J. Human Immunodeficiency Virus-Associated Gastrointestinal Disease: Common Endoscopic Biopsy Diagnoses. Pathol. Res. Int. 2011, 2011, 247923. [Google Scholar] [CrossRef]
  37. Kownhar, H.; Shankar, E.M.; Rajan, R.; Vengatesan, A.; Rao, U.A. Prevalence of Campylobacter jejuni and enteric bacterial pathogens among hospitalized HIV infected versus non-HIV infected patients with diarrhoea in southern India. Scand. J. Infect. Dis. 2007, 39, 862–866. [Google Scholar] [CrossRef]
  38. Samie, A.; Obi, C.; Barrett, L.; Powell, S.; Guerrant, R. Prevalence of Campylobacter species, Helicobacter pylori and Arcobacter species in stool samples from the Venda region, Limpopo, South Africa: Studies using molecular diagnostic methods. J. Infect. 2007, 54, 558–566. [Google Scholar] [CrossRef]
  39. Kebede, A.; Aragie, S.; Shimelis, T. The common enteric bacterial pathogens and their antimicrobial susceptibility pattern among HIV-infected individuals attending the antiretroviral therapy clinic of Hawassa university hospital, southern Ethiopia. Antimicrob. Resist. Infect. Control 2017, 6, 128. [Google Scholar] [CrossRef]
  40. Ayele, A.; Tadesse, D.; Manilal, A.; Yohanes, T.; Seid, M.; Mekuria, M.S. Prevalence of enteric bacteria and enteroparasites in human immunodeficiency virus-infected individuals with diarrhoea attending antiretroviral treatment clinic, Arba Minch General Hospital, southern Ethiopia. New Microbes New Infect. 2020, 38, 100789. [Google Scholar] [CrossRef]
  41. Tee, W.; Mijch, A. Campylobacter jejuni Bacteremia in Human Immunodeficiency Virus (HIV)- Infected and Non-HIV-Infected Patients: Comparison of Clinical Features and Review. Clin. Infect. Dis. 1998, 26, 91–96. [Google Scholar] [CrossRef]
  42. Fernández-Cruz, A.; Muñoz, P.; Mohedano, R.; Valerio, M.; Marín, M.; Alcalá, L.; Rodriguez-Créixems, M.; Cercenado, E.; Bouza, E. Campylobacter bacteremia: Clinical characteristics, incidence, and outcome over 23 years. Medicine 2010, 89, 319–330. [Google Scholar] [CrossRef] [PubMed]
  43. Rapp, C.; Imbert, P.; Fabre, R.; Cavallo, J.; Debord, T. Bactériémie et dermohypodermite à Campylobacter fetus sur cathéter à chambre implantable au cours d’une infection par le VIH. Méd. Mal. Infect. 2007, 37, 284–286. [Google Scholar] [CrossRef] [PubMed]
  44. Bravo, F.; Céspedes, A.; Morales, P.; Chanqueo, L. Bacteriemia por Campylobacter jejuni en un paciente con infección por VIH en etapa SIDA. Rev. Chil. Infectol. 2019, 36, 663–666. [Google Scholar] [CrossRef] [PubMed]
  45. Shen, Z.; Wang, Y.; Zhang, Q.; Shen, J. Antimicrobial Resistance in Campylobacter spp. Microbiol. Spectr. 2018, 6, 11. [Google Scholar] [CrossRef]
  46. Dai, L.; Sahin, O.; Grover, M.; Zhang, Q. New and alternative strategies for the prevention, control, and treatment of antibiotic-resistant Campylobacter. Transl. Res. 2020, 223, 76–88. [Google Scholar] [CrossRef]
  47. Chang, C.-H.; Lin, C.-H.; Lane, H.-Y. d-glutamate and Gut Microbiota in Alzheimer’s Disease. Int. J. Mol. Sci. 2020, 21, 2676. [Google Scholar] [CrossRef]
  48. Rouhani, S.; Griffin, N.W.; Yori, P.P.; Olortegui, M.P.; Salas, M.S.; Trigoso, D.R.; Moulton, L.H.; Houpt, E.R.; Barratt, M.J.; Kosek, M.N.; et al. Gut Microbiota Features Associated with Campylobacter Burden and Postnatal Linear Growth Deficits in a Peruvian Birth Cohort. Clin. Infect. Dis. 2020, 71, 1000–1007. [Google Scholar] [CrossRef]
  49. Nowak, R.G.; Bentzen, S.M.; Ravel, J.; Crowell, T.; Dauda, W.; Ma, B.; Liu, H.; Blattner, W.A.; Baral, S.; Charurat, M.E. Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria. AIDS 2017, 31, 857–862. [Google Scholar] [CrossRef]
  50. Li, Y.; Saxena, D.; Chen, Z.; Liu, G.; Abrams, W.R.; Phelan, J.A.; Norman, R.G.; Fisch, G.S.; Corby, P.M.; Dewhirst, F.; et al. HIV Infection and Microbial Diversity in Saliva. J. Clin. Microbiol. 2014, 52, 1400–1411. [Google Scholar] [CrossRef]
  51. Wells, J.; Bai, J.; Tsementzi, D.; Jhaney, M.C.I.; Foster, A.; Bruner, D.W.; Gillespie, T.; Li, Y.; Hu, Y.-J. Exploring the Anal Microbiome in HIV Positive and High-Risk HIV Negative Women. AIDS Res. Hum. Retrovir. 2022, 38, 228–236. [Google Scholar] [CrossRef]
  52. Cook, R.; Fulcher, J.A.; Tobin, N.H.; Li, F.; Lee, D.; Javanbakht, M.; Brookmeyer, R.; Shoptaw, S.; Bolan, R.; Aldrovandi, G.M.; et al. Effects of HIV viremia on the gastrointestinal microbiome of young MSM. AIDS 2019, 33, 793–804. [Google Scholar] [CrossRef] [PubMed]
  53. Dang, A.T.; Cotton, S.; Sankaran-Walters, S.; Li, C.-S.; Lee, C.-Y.M.; Dandekar, S.; Paster, B.J.; George, M.D. Evidence of an increased pathogenic footprint in the lingual microbiome of untreated HIV infected patients. BMC Microbiol. 2012, 12, 153. [Google Scholar] [CrossRef] [PubMed]
  54. Rajendran, P.M. Campylobacter Presenting as Erythematous Plaques on the Lower Extremity of a Man with Human Immunodeficiency Virus. Arch. Dermatol. 2006, 142, 1240–1241. [Google Scholar] [CrossRef]
  55. Eke, U.A.; Doub, J.B.; Chua, J.V. Campylobacter fetus aortitis in a patient with HIV. IDCases 2021, 25, e01169. [Google Scholar] [CrossRef] [PubMed]
  56. Laenens, D.; Plazier, M.; Van Der Hilst, J.C.H.; Messiaen, P. Campylobacter fetusspondylodiscitis in a patient with HIV infection and restored CD4 count. BMJ Case Rep. 2018, 2018, bcr2018225272. [Google Scholar] [CrossRef]
  57. Flipse, J.; Duim, B.; Wallinga, J.A.; De Wijkerslooth, L.R.H.; Bloois, L.V.D.G.-V.; Timmerman, A.J.; Zomer, A.L.; Veldman, K.T.; Wagenaar, J.A.; Bloembergen, P. A Case of Persistent Diarrhea in a Man with the Molecular Detection of Various Campylobacter species and the First Isolation of candidatus Campylobacter infans. Pathogens 2020, 9, 1003. [Google Scholar] [CrossRef]
  58. Crum-Cianflone, N.F. Salmonellosis and the gastrointestinal tract: More than just peanut butter. Curr. Gastroenterol. Rep. 2008, 10, 424–431. [Google Scholar] [CrossRef]
  59. Alaoui, Z.T.; Arabi, F.; Ihbibane, F.; Soraa, N.; Tassi, N. The first description of liver abscesses due to Salmonella enterica subsp. enterica in an African HIV-infected young woman: Case report and review of the literature. Rev. Inst. Med. Trop. São Paulo 2021, 63, e72. [Google Scholar] [CrossRef]
  60. Vidal, J.E.; Da Silva, P.R.M.; Nogueira, R.S.; Filho, F.B.; Hernandez, A.V. Liver abscess due to Salmonella enteritidis in a returned traveler with HIV infection: Case report and review of the literature. Rev. Inst. Med. Trop. São Paulo 2003, 45, 115–117. [Google Scholar] [CrossRef]
  61. Lin, P.; Ko, W.-C.; Lin, W.-C.; Li, M.-C. Liver abscess caused by coexisting Salmonella enteritidis and Entamoeba histolytica in a HIV-infected patient. J. Microbiol. Immunol. Infect. 2019, 52, 836–837. [Google Scholar] [CrossRef]
  62. Leonard, M.K.; Murrow, J.R.; Jurado, R.; Gaynes, R. Salmonella Meningitis in Adults Infected with HIV: Case Report and Review of the Literature. Am. J. Med. Sci. 2002, 323, 266–268. [Google Scholar] [CrossRef] [PubMed]
  63. Rule, R.; Mbelle, N.; Sekyere, J.O.; Kock, M.; Hoosen, A.; Said, M. A rare case of Colistin-resistant Salmonella Enteritidis meningitis in an HIV-seropositive patient. BMC Infect. Dis. 2019, 19, 806. [Google Scholar] [CrossRef] [PubMed]
  64. Maraj, A.; Kiss, A.; Luvhengo, T.E. Salmonella thyroiditis: A case report and review of the literature. S. Afr. J. Surg. 2013, 51, 149. [Google Scholar] [CrossRef] [PubMed]
  65. Huson, M.A.M.; Stolp, S.M.; van der Poll, T.; Grobusch, M.P. Community-Acquired Bacterial Bloodstream Infections in HIV-Infected Patients: A Systematic Review. Clin. Infect. Dis. 2013, 58, 79–92. [Google Scholar] [CrossRef] [Green Version]
  66. Qu, Z.; McMahon, B.H.; Perkins, D.J.; Hyman, J.M. Staged progression epidemic models for the transmission of invasive nontyphoidal Salmonella (iNTS) with treatment. Math. Biosci. Eng. 2021, 18, 1529–1549. [Google Scholar] [CrossRef]
  67. Hung, C.-C.; Hung, M.-N.; Hsueh, P.-R.; Chang, S.-Y.; Chen, M.-Y.; Hsieh, S.-M.; Sheng, W.-H.; Sun, H.-Y.; Huang, Y.-T.; Lo, Y.-C.; et al. Risk of Recurrent Nontyphoid Salmonella Bacteremia in HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy and an Increasing Trend of Fluoroquinolone Resistance. Clin. Infect. Dis. 2007, 45, e60–e67. [Google Scholar] [CrossRef]
  68. Keddy, K.H.; Takuva, S.; Musekiwa, A.; Puren, A.J.; Sooka, A.; Karstaedt, A.; Klugman, K.P.; Angulo, F.J. An association between decreasing incidence of invasive non-typhoidal salmonellosis and increased use of antiretroviral therapy, Gauteng Province, South Africa, 2003–2013. PLoS ONE 2017, 12, e0173091. [Google Scholar] [CrossRef]
  69. Gordon, M.A. Salmonella infections in immunocompromised adults. J. Infect. 2008, 56, 413–422. [Google Scholar] [CrossRef]
  70. Gordon, M.; Banda, H.T.; Gondwe, M.; Gordon, S.; Boeree, M.J.; Walsh, A.L.; Corkill, J.E.; Hart, C.A.; Gilks, C.; Molyneux, M.E. Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: High mortality and frequent recrudescence. AIDS 2002, 16, 1633–1641. [Google Scholar] [CrossRef]
  71. Levine, M.M.; Farag, T.H. Invasive Salmonella Infections and HIV in Northern Tanzania. Clin. Infect. Dis. 2011, 52, 349–351. [Google Scholar] [CrossRef]
  72. Keddy, K.H.; Musekiwa, A.; Sooka, A.; Karstaedt, A.; Nana, T.; Seetharam, S.; Nchabaleng, M.; Lekalakala, R.; Angulo, F.J.; Klugman, K.P. Clinical and microbiological features of invasive nontyphoidal Salmonella associated with HIV-infected patients, Gauteng Province, South Africa. Medicine 2017, 96, e6448. [Google Scholar] [CrossRef]
  73. Belay, A.; Ashagrie, M.; Seyoum, B.; Alemu, M.; Tsegaye, A. Prevalence of enteric pathogens, intestinal parasites and resistance profile of bacterial isolates among HIV infected and non-infected diarrheic patients in Dessie Town, Northeast Ethiopia. PLoS ONE 2020, 15, e0243479. [Google Scholar] [CrossRef]
  74. Mahon, B.E.; Fields, P.I. Invasive Infections with Nontyphoidal Salmonella in Sub-Saharan Africa. Microbiol. Spectr. 2016, 4, 341–357. [Google Scholar] [CrossRef]
  75. Feasey, N.A.; Dougan, G.; Kingsley, R.A.; Heyderman, R.S.; Gordon, M.A. Invasive non-typhoidal salmonella disease: An emerging and neglected tropical disease in Africa. Lancet 2012, 379, 2489–2499. [Google Scholar] [CrossRef]
  76. Nga, T.V.T.; Parry, C.M.; Le, T.; Lan, N.P.H.; Diep, T.S.; Campbell, J.I.; Hoang, N.V.M.; Dung, L.T.; Wain, J.; Dolecek, C.; et al. The decline of typhoid and the rise of non-typhoid salmonellae and fungal infections in a changing HIV landscape: Bloodstream infection trends over 15 years in southern Vietnam. Trans. R. Soc. Trop. Med. Hyg. 2012, 106, 26–34. [Google Scholar] [CrossRef]
  77. Kariuki, S.; Onsare, R.S. Epidemiology and Genomics of Invasive Nontyphoidal Salmonella Infections in Kenya. Clin. Infect. Dis. 2015, 61, S317–S324. [Google Scholar] [CrossRef]
  78. Kenga, D.B.; Gebretsadik, T.; Simbine, S.; Maússe, F.E.; Charles, P.; Zaqueu, E.; Fernando, H.F.; Manjate, A.; Sacarlal, J.; Moon, T.D. Community-acquired bacteremia among HIV-infected and HIV-exposed uninfected children hospitalized with fever in Mozambique. Int. J. Infect. Dis. 2021, 109, 99–107. [Google Scholar] [CrossRef]
  79. Mather, A.E.; Phuong, T.L.T.; Gao, Y.; Clare, S.; Mukhopadhyay, S.; Goulding, D.A.; Hoang, N.T.D.; Tuyen, H.T.; Lan, N.P.H.; Thompson, C.N.; et al. New Variant of Multidrug-Resistant Salmonella enterica Serovar Typhimurium Associated with Invasive Disease in Immunocompromised Patients in Vietnam. mBio 2018, 9, e01056-18. [Google Scholar] [CrossRef]
  80. Gordon, M.A.; Graham, S. Invasive salmonellosis in Malawi. J. Infect. Dev. Ctries. 2008, 2, 438–442. [Google Scholar] [CrossRef]
  81. Monack, D.M. Salmonella persistence and transmission strategies. Curr. Opin. Microbiol. 2011, 15, 100–107. [Google Scholar] [CrossRef]
  82. Keddy, K.H.; Dwarika, S.; Crowther, P.; Perovic, O.; Wadula, J.; Hoosen, A.; Sooka, A.; Crewe-Brown, H.H.; Smith, A.M. Genotypic and demographic characterization of invasive isolates of Salmonella Typhimurium in HIV co-infected patients in South Africa. J. Infect. Dev. Ctries. 2009, 3, 585–592. [Google Scholar] [CrossRef] [PubMed]
  83. Crump, J.A.; Ramadhani, H.O.; Morrissey, A.B.; Saganda, W.; Mwako, M.S.; Yang, L.-Y.; Chow, S.-C.; Morpeth, S.C.; Reyburn, H.; Njau, B.N.; et al. Invasive Bacterial and Fungal Infections Among Hospitalized HIV-Infected and HIV-Uninfected Adults and Adolescents in Northern Tanzania. Clin. Infect. Dis. 2011, 52, 341–348. [Google Scholar] [CrossRef]
  84. MacLennan, C.A.; Gilchrist, J.J.; Gordon, M.A.; Cunningham, A.F.; Cobbold, M.; Goodall, M.; Kingsley, R.A.; van Oosterhout, J.J.G.; Msefula, C.L.; Mandala, W.L.; et al. Dysregulated Humoral Immunity to Nontyphoidal Salmonella in HIV-Infected African Adults. Science 2010, 328, 508–512. [Google Scholar] [CrossRef]
  85. Gordon, M.A.; Gordon, S.B.; Musaya, L.; Zijlstra, E.E.; Molyneux, M.E.; Read, R.C. Primary macrophages from HIV-infected adults show dysregulated cytokine responses to Salmonella, but normal internalization and killing. AIDS 2007, 21, 2399–2408. [Google Scholar] [CrossRef]
  86. Schreiber, F.; Lynn, D.J.; Houston, A.; Peters, J.; Mwafulirwa, G.; Finlay, B.B.; Brinkman, F.S.L.; Hancock, R.E.W.; Heyderman, R.S.; Dougan, G.; et al. The Human Transcriptome during Nontyphoid Salmonella and HIV Coinfection Reveals Attenuated NFκB-Mediated Inflammation and Persistent Cell Cycle Disruption. J. Infect. Dis. 2011, 204, 1237–1245. [Google Scholar] [CrossRef]
  87. Cacemiro, M.C.; Espíndola, M.S.; Galvão-Lima, L.J.; Soares, L.S.; Fontanari, C.; Prata, M.A.; Campioni, F.; Falcão, J.P.; Bollela, V.R.; Frantz, F.G. Immune Response Against Salmonella Enteritidis Is Unsettled by HIV Infection. In Advances in Microbiology, Infectious Diseases and Public Health; Springer: Berlin/Heidelberg, Germany, 2017; Volume 220, pp. 29–39. [Google Scholar]
  88. Lê-Bury, G.; Deschamps, C.; Kizilyaprak, C.; Blanchard, W.; Daraspe, J.; Dumas, A.; Gordon, M.; Hinton, J.; Humbel, B.; Niedergang, F. Increased intracellular survival of Salmonella Typhimurium ST313 in HIV-1-infected primary human macrophages is not associated with Salmonella hijacking the HIV compartment. Biol. Cell 2020, 112, 92–101. [Google Scholar] [CrossRef]
  89. Lê-Bury, G.; Niedergang, F. Defective Phagocytic Properties of HIV-Infected Macrophages: How Might They Be Implicated in the Development of Invasive Salmonella Typhimurium? Front. Immunol. 2018, 9, 531. [Google Scholar] [CrossRef]
  90. Dandekar, S.; George, M.D.; Baumler, A. Th17 cells, HIV and the gut mucosal barrier. Curr. Opin. HIV AIDS 2010, 5, 173–178. [Google Scholar] [CrossRef]
  91. Thomas, J.; Govender, N.; McCarthy, K.M.; Erasmus, L.K.; Doyle, T.J.; Allam, M.; Ismail, A.; Ramalwa, N.; Sekwadi, P.; Ntshoe, G.; et al. Outbreak of Listeriosis in South Africa Associated with Processed Meat. N. Engl. J. Med. 2020, 382, 632–643. [Google Scholar] [CrossRef]
  92. Lepe, J.A. Aspectos actuales de la listeriosis. Med. Clin. 2020, 154, 453–458. [Google Scholar] [CrossRef]
  93. Ricart, C.; Tornero, C.; Pardo, J.; Navarro, D. Sepsis fulminante por Listeria monocytogenes en un paciente con infección por el virus de la inmunodeficiencia humana [Fulminant sepsis by Listeria monocytogenes in a patient with coinfection by human immunodeficiency virus]. Enferm. Infecc. Microbiol. Clín. 1999, 17, 147–148. [Google Scholar] [PubMed]
  94. Ewert, D.P.; Lieb, L.; Hayes, P.S.; Reeves, M.W.; Mascola, L. Listeria monocytogenes Infection and Serotype Distribution Among HIV-Infected Persons in Los Angeles County, 1985–1992. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995, 8, 461–465. [Google Scholar] [CrossRef] [PubMed]
  95. Calubiran, O.V.; Horiuchi, J.; Klein, N.C.; Cunha, B.A. Listeria monocytogenes meningitis in a human immunodeficiency vi-rus-positive patient undergoing hemodialysis. Heart Lung J. Crit. Care 1990, 19, 21–23. [Google Scholar]
  96. Roldán, A.; Gutiérrez, A.; Jiménez, J.; Agulla, A.; Zancada, F.; Fernández, A. Meningitis por Listeria e infeccción por VIH [Listeria meningitis and HIV infection]. Rev. Clin. Esp. 1991, 188, 197–198. [Google Scholar]
  97. Patil, A.B.; Nadiger, S.; Chandrasekhar, M.R.; Halesh, L.H.; Kumar, M. Listeria monocytogenes meningitis: An uncommon op-portunistic infection in HIV/AIDS. Indian J. Pathol. Microbiol. 2007, 50, 671–673. [Google Scholar]
  98. Schutte, C.-M.; Van Der Meyden, C.H.; Kakaza, M.; Lockhat, Z.; Van Der Walt, E. Life-threatening Listeria meningitis: Need for revision of South African acute bacterial meningitis treatment guidelines. S. Afr. Med. J. 2019, 109, 296–298. [Google Scholar] [CrossRef]
  99. García Castaño, J.; Farfán Sedano, A.I.; Gironés Pérez, J.M.; Ortiz Vega, M. Meningitis por Listeria monocytogenes tras colon-oscopia en paciente con infección por VIH y citomegalovirus [Listeria monocytogenes meningitis in a patient with HIV infection and cytomegalovirus infection after colonoscopy]. An. Med. Interna 2001, 18, 398–399. [Google Scholar]
  100. Valencia Ortega, M.E.; Enríquez Crego, A.; Laguna Cuesta, F.; Ortega Millán, G.; González Lahoz, J.M. Listeriosis: Una infección poco frecuente en pacientes con VIH. An. Med. Interna 2000, 17, 649–651. [Google Scholar] [CrossRef]
  101. Tsai, S.H.; Chu, S.J.; Wu, C.P.; Wang, N.C. Listerial meningitis in a patient with undiagnosed acquired immunodeficiency syndrome: Ampicillin should be added to the empirical antibiotic coverage. Emerg. Med. J. 2006, 23, e50. [Google Scholar] [CrossRef]
  102. Ba-Fall, K.M.; Wade, B.; Hovette, P.; Colbachini, P.; Mbaye, P.S.; Debonne, J.M. L’infection a listeria. A propos des deux premiers cas diagnostiqués a l’Hôpital Principal de Dakar. Dakar Med. 2003, 48, 54–56. [Google Scholar]
  103. Opperman, C.J.; Bamford, C. Co-infection with Streptococcus pneumoniae and Listeria monocytogenes in an immunocompromised patient. S. Afr. Med. J. 2018, 108, 386–388. [Google Scholar] [CrossRef] [PubMed]
  104. Guerra, J.; Muinelo, I.; Pérez-Simón, M.R.; Blanco, B.; Carro, J.A.; Alcoba, M. Listeriosis en pacientes con infección por el virus de la inmunodeficiencia humana en España. Aportación de tres casos y revisión de la literature. Enferm. Infecc. Microbiol. Clin. 2004, 22, 18–21. [Google Scholar] [CrossRef]
  105. Freitag, I.G.R.; Pereira, R.D.C.L.; Machado, E.S.; Hofer, E.; Vallim, D.C.; Hofer, C.B. Seroprevalence of Listeria monocytogenes in HIV infected pregnant women from Brazil. Braz. J. Infect. Dis. 2021, 25, 101635. [Google Scholar] [CrossRef] [PubMed]
  106. Freitag, I.G.R.; Pereira, R.D.C.L.; Machado, E.S.; Hofer, E.; Vallim, D.C.; Hofer, C.B. Prevalence of Listeria monocytogenes fecal carriers in HIV-infected and -uninfected pregnant women from Brazil. Braz. J. Microbiol. 2021, 52, 2081–2084. [Google Scholar] [CrossRef] [PubMed]
  107. Gunst, J.D.; Jensen-Fangel, S. A mycotic abdominal aortic aneurysm caused by Listeria monocytogenes in a patient with HIV infection. BMJ Case Rep. 2014, 2014, bcr2013202712. [Google Scholar] [CrossRef]
  108. Sia, C.; Wilson, S.; Ananda-Rajah, M.; Mills, J.; Aung, A.K. Listeria monocytogenes peritonitis in an HIV infected patient. Clin. Nephrol. 2017, 87, 267–270. [Google Scholar] [CrossRef]
  109. Roca, B.; Díaz, M.D.; Roca, M. Acute prostatitis probably due to Listeria monocytogenes in an HIV-infected patient. Int. J. STD AIDS 2014, 26, 837–838. [Google Scholar] [CrossRef]
  110. Maddocks, L.; Khanna, P.; Reay-Jones, N. A complicated case of cholecystitis, listeriosis and HIV/AIDS. BMJ Case Rep. 2011, 2011, bcr0820103292. [Google Scholar] [CrossRef]
  111. Rossi, P.; Network, T.E.; Tamarozzi, F.; Galati, F.; Akhan, O.; Cretu, C.M.; Vutova, K.; Siles-Lucas, M.; Brunetti, E.; Casulli, A. The European Register of Cystic Echinococcosis, ERCE: State-of-the-art five years after its launch. Parasites Vectors 2020, 13, 236. [Google Scholar] [CrossRef]
  112. Petrone, L.; Vanini, V.; Petruccioli, E.; Ettorre, G.M.; Schinina’, V.; Rizzi, E.B.; Ludovisi, A.; Corpolongo, A.; Ippolito, G.; Pozio, E.; et al. Polyfunctional Specific Response to Echinococcus Granulosus Associates to the Biological Activity of the Cysts. PLoS Negl. Trop. Dis. 2015, 9, e0004209. [Google Scholar] [CrossRef]
  113. Wahlers, K.; Menezes, C.N.; Romig, T.; Kern, P.; Grobusch, M.P. Cystic echinococcosis in South Africa: The worst yet to come? Acta Trop. 2013, 128, 1–6. [Google Scholar] [CrossRef] [PubMed]
  114. Wahlers, K.; Menezes, C.N.; Wong, M.; Mogoye, B.; Frean, J.; Romig, T.; Kern, P.; Grobusch, M.P. Human cystic echinococcosis in South Africa. Acta Trop. 2011, 120, 179–184. [Google Scholar] [CrossRef] [PubMed]
  115. Noormahomed, E.V.; Nhacupe, N.; Mascaró-Lazcano, C.; Mauaie, M.N.; Buene, T.; Funzamo, C.A.; Benson, C.A. A Cross-sectional Serological Study of Cysticercosis, Schistosomiasis, Toxocariasis and Echinococcosis in HIV-1 Infected People in Beira, Mozambique. PLoS Negl. Trop. Dis. 2014, 8, e3121. [Google Scholar] [CrossRef] [PubMed]
  116. Ghasemirad, H.; Bazargan, N.; Shahesmaeili, A.; Harandi, M.F. Echinococcosis in immunocompromised patients: A systematic review. Acta Trop. 2022, 232, 106490. [Google Scholar] [CrossRef]
  117. Ran, B.; Shao, Y.; Guo, Y.; Yimiti, Y.; Aji, T.; Jia, J.; Shayiding, P.; Jiang, T.; Cheng, L.; Li, J.; et al. Surgical treatment of hepatic cystic echinococcosis in patients co-infected with HIV/AIDS. J. Helminthol. 2015, 90, 125–128. [Google Scholar] [CrossRef]
  118. Javed, A.; Kalayarasan, R.; Agarwal, A.K. Liver Hydatid with HIV Infection: An Association? J. Gastrointest. Surg. 2012, 16, 1275–1277. [Google Scholar] [CrossRef]
  119. Ozoilo, K.N.; Iya, D.; Kidmas, A.T.; Uwumarogie, O.; Hassan, S.; Kidman, A. Anterior abdominal wall hydatid cyst: An unusual presentation. Niger. J. Med. 2007, 16, 181–182. [Google Scholar] [CrossRef]
  120. Erayman, I.; Kalkan, E.; Erdi, F.; Kerimoglu, Ü.; Esen, H. Primary spinal hydatid cyst in a patient with acquired immunodeficiency syndrome. Eur. Spine J. 2010, 20 (Suppl. 2), S235–S238. [Google Scholar] [CrossRef]
  121. Shenoy, V.V.; Joshi, S.R.; Aklujkar, A.P.; Kotwal, V.S.; Nadkarni, N.A.; Ramraje, N.N. Pulmonary hydatid cyst in HIV-1 disease. J. Assoc. Physicians India 2005, 53, 1070–1072. [Google Scholar]
  122. Sharifi, Y.; Sadjjadi, S.M.; Dailami, H.N.; Jafari, S.H.; Anbardar, M.H.; Khosravi, M.B. Cystic Echinococcosis/Hydatid Cyst Coinfection with HIV: A Report from Shiraz, Iran. Can. J. Gastroenterol. Hepatol. 2021, 2021, 8844104. [Google Scholar] [CrossRef]
  123. Ramos, J.M.; Masia, M.; Padilla, S.; Bernal, E.; Martin-Hidalgo, A.; Gutiérrez, F. Fatal infection due to larval cysts of cestodes (neurocysticercosis and hydatid disease) in human immunodeficiency virus (HIV) infected patients in Spain: Report of two cases. Scand. J. Infect. Dis. 2007, 39, 719–723. [Google Scholar] [CrossRef] [PubMed]
  124. Zingg, W.; Renner-Schneiter, E.C.; Pauli-Magnus, C.; Renner, E.L.; van Overbeck, J.; Schläpfer, E.; Weber, M.; Weber, R.; Opravil, M.; Gottstein, B.; et al. Alveolar Echinococcosis of the Liver in an Adult with Human Immunodeficiency Virus Type-1 Infection. Infection 2004, 32, 299–302. [Google Scholar] [CrossRef] [PubMed]
  125. Sailer, M.; Soelder, B.; Allerberger, F.; Zaknun, D.; Feichtinger, H.; Gottstein, B. Alveolar echinococcosis of the liver in a six-year-old girl with acquired immunodeficiency syndrome. J. Pediatr. 1997, 130, 320–323. [Google Scholar] [CrossRef]
  126. de Almeida, F.B.; Corrêa, C.L.; de Siqueira, N.G.; Carvalho, N.V.F.d.S.; Rodrigues-Silva, R.; de Andrade, A.F.B.; Machado-Silva, J.R. Histopathological findings of an uncommon co-infection: Echinococcus vogeli, HIV, hepatitis C virus, and hepatitis B virus. Int. J. Infect. Dis. 2013, 17, e925–e927. [Google Scholar] [CrossRef]
  127. Khademi, F.; Yousefi-Avarvand, A.; Sahebkar, A.; Ghanbari, F.; Vaez, H. Bacterial Co-infections in HIV/AIDS-positive Subjects: A Systematic Review and Meta-analysis. Folia Medica 2018, 60, 339–350. [Google Scholar] [CrossRef]
  128. Abdollahi, A.; Morteza, A.; Khalilzadeh, O.; Rasoulinejad, M. Brucellosis serology in HIV-infected patients. Int. J. Infect. Dis. 2010, 14, e904–e906. [Google Scholar] [CrossRef]
  129. Hajiabdolbaghi, M.; Rasoulinejad, M.; Abdollahi, A.; Paydary, K.; Valiollahi, P.; SeyedAlinaghi, S.; Parsa, M.; Jafari, S. Brucella infection in HIV infected patients. Acta Med. Iran. 2011, 49, 801–805. [Google Scholar]
  130. Baroncelli, S.; Tarantino, M.; Galluzzo, C.M.; Liotta, G.; Orlando, S.; Sagno, J.B.; Luhanga, R.; Andreotti, M.; Petrucci, P.; Amici, R.; et al. Seroprevalence of Brucella Infection in a Cohort of HIV-Positive Malawian Pregnant Women Living in Urban Areas. Vector-Borne Zoonotic Dis. 2022, 22, 263–266. [Google Scholar] [CrossRef]
  131. Paul, J.; Gilks, C.; Batchelor, B.; Ojoo, J.; Amir, M.; Selkon, J. Serological responses to brucellosis in HIV-seropositive patients. Trans. R. Soc. Trop. Med. Hyg. 1995, 89, 228–230. [Google Scholar] [CrossRef]
  132. Pedro-Botet, J.; Coll, J.; Auguet, T.; Rublés-Prat, J. Brucellosis and HIV infection: A casual association? AIDS 1992, 6, 1039–1040. [Google Scholar] [CrossRef]
  133. Lucero, N.E.; Maldonado, P.L.; Kaufman, S.; Escobar, G.I.; Boeri, E.; Jacob, N.R. Brucella canis Causing Infection in an HIV-Infected Patient. Vector-Borne Zoonotic Dis. 2010, 10, 527–529. [Google Scholar] [CrossRef] [PubMed]
  134. Lawaczeck, E.; Toporek, J.; Cwikla, J.B.; Mathison, B.A. Brucella canis in a HIV-Infected Patient. Zoonoses Public Health 2010, 58, 150–152. [Google Scholar] [CrossRef] [PubMed]
  135. Ibarra, V.; Blanco, J.; Metola, L.; Oteo, J. Relapsing brucellosis in a patient infected with the human immunodeficiency virus (HIV). Clin. Microbiol. Infect. 2003, 9, 1259–1260. [Google Scholar] [CrossRef]
  136. Rubio Gutiérrez, A.; Portu Zapirain, J.; Zubizarreta García, J.; Ayensa Dean, C. Meningitis por Brucella abortus en un paciente con infección por el virus de la inmunodeficiencia humana [Brucella abortus meningitis in a patient with HIV infection]. Med. Clin. 1992, 99, 678. [Google Scholar]
  137. Dong, S.-B.; Wang, L.-P.; Wu, C.-X.; Li, F.; Yue, Y.; Piao, D.-R.; Zhao, H.-Y.; Jiang, H. A case of brucellosis concomitant with HIV infection in China. Infect. Dis. Poverty 2020, 9, 6. [Google Scholar] [CrossRef] [PubMed]
  138. Moreno, S.; Ariza, J.; Espinosa, F.J.; Podzamczer, D.; Miró, J.M.; Rivero, A.; Rodríguez-Zapata, M.; Arrizabalaga, J.; Mateos, R.; Herrero, F. Brucellosis in patients infected with the human immunodeficiency virus. Eur. J. Clin. Microbiol. 1998, 17, 319–326. [Google Scholar] [CrossRef]
  139. Abdad, M.Y.; Abdallah, R.A.; Fournier, P.-E.; Stenos, J.; Vasoo, S. A Concise Review of the Epidemiology and Diagnostics of Rickettsioses: Rickettsia and Orientia spp. J. Clin. Microbiol. 2018, 56, e01728-17. [Google Scholar] [CrossRef]
  140. Pawełczyk, A.; Bednarska, M.; Kowalska, J.D.; Uszyńska-Kałuża, B.; Radkowski, M.; Welc-Falęciak, R. Seroprevalence of six pathogens transmitted by the Ixodes ricinus ticks in asymptomatic individuals with HIV infection and in blood donors. Sci. Rep. 2019, 9, 2117. [Google Scholar] [CrossRef]
  141. Ekala, M.T.; Gresenguet, G.; Belec, L. Séroprévalence des infections à rickettsies du groupe des fièvres boutonneuses ou ap-parentées à Bangui (République centrafricaine). Bull. Soc. Pathol. Exot. 1995, 88, 126–128. [Google Scholar]
  142. Nogueras, M.M.; Pons, I.; Sanfeliu, I.; Sala, M.; Segura, F. Serosurvey ofRickettsia typhiandRickettsia felisin HIV-infected patients. Microbiol. Immunol. 2014, 58, 257–259. [Google Scholar] [CrossRef]
  143. Colomba, C.; Siracusa, L.; Madonia, S.; Saporito, L.; Bonura, C.; DE Grazia, S.; Giammanco, G. A case of spotted fever rickettsiosis in a human immunodeficiency virus-positive patient. J. Med. Microbiol. 2013, 62 Pt 9, 1363–1364. [Google Scholar] [CrossRef] [PubMed]
  144. Sanders, S.; Di Costanzo, D.; Leach, J.; Levy, H.; Srinivasan, K.; Zaki, S.R.; Comer, J.A.; Paddock, C.D. Rickettsialpox in a patient with HIV infection. J. Am. Acad. Dermatol. 2003, 48, 286–289. [Google Scholar] [CrossRef]
  145. Babu, K.; Sudheer, B.; Murthy, K. Bilateral arterial occlusions masking retinitis in a HIV-positive male. Indian J. Ophthalmol. 2018, 66, 332–334. [Google Scholar] [CrossRef] [PubMed]
  146. Stanek, G.; Wormser, G.P.; Gray, J.; Strle, F. Lyme borreliosis. Lancet 2012, 379, 461–473. [Google Scholar] [CrossRef]
  147. Schotthoefer, A.M.; Frost, H.M. Ecology and Epidemiology of Lyme Borreliosis. Clin. Lab. Med. 2015, 35, 723–743. [Google Scholar] [CrossRef]
  148. Schlesinger, I.; Mehta, H.; Arlievsky, N. Lyme Arthritis in a Child with HIV. Orthopedics 2001, 24, 609–610. [Google Scholar] [CrossRef]
  149. Lübbe, J.; Schlüpen, E.M.; Fierz, W.; Panizzon, R.G.; Burg, G. Identification of Borrelia afzelii in a juxta-articular fibroid nodule from a human immunodeficiency virus-positive patient with acrodermatitis chronica atrophicans. Arch. Dermatol. 1995, 131, 1341–1342. [Google Scholar] [CrossRef]
  150. Okwori, E.E. Spirochaetemia in a HIV positive patient. Niger. J. Med. 2006, 15, 455–456. [Google Scholar] [CrossRef]
  151. Dudle, G.; Opravil, M.; Lüthy, R.; Weber, R. Meningitis nach akuter Borrelia-burgdorferi-Infektion und HIV-Infektion. DMW-Dtsch. Med. Wochenschr. 1997, 122, 1178–1180. [Google Scholar] [CrossRef]
  152. Černý, R.; Machala, L.; Bojar, M.; Rozsypal, H.; Pícha, D. Neuroborreliosis in an HIV-1 Positive Patient. Infection 2006, 34, 100–102. [Google Scholar] [CrossRef]
  153. Traversat, P.; Lauzeral, A.; Michalak, S.; Mahieu, R.; Berteau, F.; Dubée, V. Exacerbation of acrodermatitis chronica atrophicans under antiretroviral treatment in an HIV-infected patient. J. Eur. Acad. Dermatol. Venereol. 2022, 36, e107–e109. [Google Scholar] [CrossRef] [PubMed]
  154. Salama, C.; Finch, D.; Bottone, E.J. Fusospirochetosis causing necrotic oral ulcers in patients with HIV infection. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol. 2004, 98, 321–323. [Google Scholar] [CrossRef]
  155. de Pont, C.D.; Lowe, S.H.; Goossens, V.J. Successful treatment of neuroborreliosis in an HIV patient with simultaneous Borrelia, HIV-1 and Epstein–Barr virus genomes in liquor. AIDS 2013, 27, 1196–1197. [Google Scholar] [CrossRef] [PubMed]
  156. Cordoliani, F.; Vignon-Pennamen, M.D.; Assous, M.V.; Vabres, P.; Dronne, P.; Rybojad, M.; Morel, P. Atypical Lyme borreliosis in an HIV-infected man. Br. J. Dermatol. 1997, 137, 437–439. [Google Scholar] [CrossRef] [PubMed]
  157. Van Burgel, N.D.; Oosterloo, M.; Kroon, F.P.; Van Dam, A.P. Severe course of Lyme neuroborreliosis in an HIV-1 positive patient; case report and review of the literature. BMC Neurol. 2010, 10, 117. [Google Scholar] [CrossRef]
  158. Bratzke, B.; Stadler, R.; Gollnick, H.; Rolfs, A.; Höffken, G. Borrelia-burgdorferi-induziertes Pseudolymphom mit Erregeranzüchtung bei einem HIV-1-positiven Kranken. Hautarzt 1989, 40, 504–509. [Google Scholar]
  159. Doshi, S.; Keilp, J.G.; Strobino, B.; McElhiney, M.; Rabkin, J.; Fallon, B.A. Depressive Symptoms and Suicidal Ideation Among Symptomatic Patients with a History of Lyme Disease vs Two Comparison Groups. J. Psychosom. Res. 2018, 59, 481–489. [Google Scholar] [CrossRef]
  160. Bremell, D.; Mattsson, N.; Edsbagge, M.; Blennow, K.; Andreasson, U.; Wikkelsö, C.; Zetterberg, H.; Hagberg, L. Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection. BMC Neurol. 2013, 13, 2. [Google Scholar] [CrossRef]
  161. Burza, S.; Croft, S.L.; Boelaert, M. Leishmaniasis. Lancet 2018, 392, 951–970. [Google Scholar] [CrossRef]
  162. Monge-Maillo, B.; Norman, F.F.; Cruz, I.; Alvar, J.; Lopez-Vélez, R. Visceral Leishmaniasis and HIV Coinfection in the Mediterranean Region. PLoS Negl. Trop. Dis. 2014, 8, e3021. [Google Scholar] [CrossRef]
  163. Pintado, V.; Martin-Rabadan, P.; Rivera, M.L.; Moreno, S.; Bouza, E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: A comparative study. Medicine 2001, 80, 54–73. [Google Scholar] [CrossRef]
  164. García-Río, I.; Daudén, E.; Ballestero-Díez, M.; Fraga, J.; García-Díez, A. Leishmaniasis y nodulosis reumatoide en paciente con infección por el virus de la inmunodeficiencia humana. Actas Dermo-Sifiliogr. 2010, 101, 164–167. [Google Scholar] [CrossRef]
  165. Dujardin, A.; de La Blanchardière, A.; Dina, J.; Stefic, K.; Ravel, C.; Bonhomme, J.; Verdon, R.; Fournier, A.L. Case Report: Leishmania and HIV Co-Diagnosis: How to Understand Medical History? Front. Immunol. 2021, 12, 669723. [Google Scholar] [CrossRef] [PubMed]
  166. Colomba, C.; Saporito, L.; Vitale, F.; Reale, S.; Vitale, G.; Casuccio, A.; Tolomeo, M.; Maranto, D.; Rubino, R.; Di Carlo, P.; et al. Cryptic Leishmania infantum infection in Italian HIV infected patients. BMC Infect. Dis. 2009, 9, 199. [Google Scholar] [CrossRef] [Green Version]
  167. Alvar, J.; Aparicio, P.; Aseffa, A.; Den Boer, M.; Cañavate, C.; Dedet, J.-P.; Gradoni, L.; Ter Horst, R.; López-Vélez, R.; Moreno, J. The Relationship between Leishmaniasis and AIDS: The Second 10 Years. Clin. Microbiol. Rev. 2008, 21, 334–359. [Google Scholar] [CrossRef]
  168. Cacopardo, B.; Nigro, L.; Preiser, W.; Famà, A.; Satariano, M.; Braner, J.; Celesia, B.; Weber, B.; Russo, R.; Doerr, H. Prolonged Th2 cell activation and increased viral replication in HIV-Leishmania co-infected patients despite treatment. Trans. R. Soc. Trop. Med. Hyg. 1996, 90, 434–435. [Google Scholar] [CrossRef]
  169. Maksoud, S.; Ortega, J.; Hidalgo, M.; Rangel, H. Leishmania donovani and HIV co-infection in vitro: Identification and characterization of main molecular players. Acta Trop. 2021, 228, 106248. [Google Scholar] [CrossRef]
  170. Andreani, G.; Lodge, R.; Richard, D.; Tremblay, M.J. Mechanisms of interaction between protozoan parasites and HIV. Curr. Opin. HIV AIDS 2012, 7, 275–281. [Google Scholar] [CrossRef]
  171. Okwor, I.; Uzonna, J.E. The immunology of Leishmania/HIV co-infection. Immunol. Res. 2013, 56, 163–171. [Google Scholar] [CrossRef]
  172. Cota, G.F.; de Sousa, M.R.; Rabello, A. Predictors of Visceral Leishmaniasis Relapse in HIV-Infected Patients: A Systematic Review. PLoS Negl. Trop. Dis. 2011, 5, e1153. [Google Scholar] [CrossRef]
  173. Mccollum, A.M.; Damon, I.K. Human Monkeypox. Clin. Infect. Dis. 2013, 58, 260–267. [Google Scholar] [CrossRef] [PubMed]
  174. Hammerschlag, Y.; MacLeod, G.; Papadakis, G.; Sanchez, A.A.; Druce, J.; Taiaroa, G.; Savic, I.; Mumford, J.; Roberts, J.; Caly, L.; et al. Monkeypox infection presenting as genital rash, Australia, May 2022. Eurosurveillance 2022, 27, 2200411. [Google Scholar] [CrossRef] [PubMed]
Table
Table 1. Epidemiology of some of the most common zoonoses in European countries as reported by the ECDC bulletin, referring to 2020 (note: monkeypox epidemiology updated to 7 July 2022).
Table 1. Epidemiology of some of the most common zoonoses in European countries as reported by the ECDC bulletin, referring to 2020 (note: monkeypox epidemiology updated to 7 July 2022).
Zoonoses Epidemiology in EU in 2020CasesHospitalizationsDeaths
Campylobacteriosis120,946860545
Salmonellosis52,702614957
Listeriosis1876780167
Echinococcosis488440
Brucellosis128362
Rickettsiosis---
Borreliosis---
Leishmaniasis---
Monkeypox *4908 *-0 *
Epidemiology of most common zoonoses; * Refers to July 2022 epidemiology.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Russotto, Y.; Micali, C.; Pellicanò, G.F.; Nunnari, G.; Venanzi Rullo, E. HIV and Mediterranean Zoonoses: A Review of the Literature. Infect. Dis. Rep. 2022, 14, 694-709. https://doi.org/10.3390/idr14050075

AMA Style

Russotto Y, Micali C, Pellicanò GF, Nunnari G, Venanzi Rullo E. HIV and Mediterranean Zoonoses: A Review of the Literature. Infectious Disease Reports. 2022; 14(5):694-709. https://doi.org/10.3390/idr14050075

Chicago/Turabian Style

Russotto, Ylenia, Cristina Micali, Giovanni Francesco Pellicanò, Giuseppe Nunnari, and Emmanuele Venanzi Rullo. 2022. "HIV and Mediterranean Zoonoses: A Review of the Literature" Infectious Disease Reports 14, no. 5: 694-709. https://doi.org/10.3390/idr14050075

Article Metrics

Back to TopTop